Elizabeth E. Reed's most recent trade in Travere Therapeutics Inc was a trade of 37,500 Employee stock option (right to buy) done . Disclosure was reported to the exchange on Sept. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 15 Sep 2026 | 37,500 | 0 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 15 Sep 2026 | 37,500 | 142,889 (0%) | 0% | 15.5 | 579,750 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 62.03 per share. | 15 Sep 2026 | 21,926 | 120,963 (0%) | 0% | 62.0 | 1,359,971 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 62.63 per share. | 15 Sep 2026 | 13,874 | 107,089 (0%) | 0% | 62.6 | 868,965 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 63.69 per share. | 15 Sep 2026 | 1,400 | 105,689 (0%) | 0% | 63.7 | 89,166 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 65.31 per share. | 15 Sep 2026 | 300 | 105,389 (0%) | 0% | 65.3 | 19,593 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.96 per share. | 04 May 2026 | 20,000 | 125,211 (0%) | 0% | 18.0 | 359,200 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 04 May 2026 | 20,000 | 105,211 (0%) | 0% | 45 | 900,000 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 04 May 2026 | 20,000 | 0 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 04 May 2026 | 8,500 | 8,500 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 04 May 2026 | 4,250 | 4,250 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2026 | 4,250 | 109,461 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 46.65 per share. | 04 May 2026 | 2,174 | 107,287 (0%) | 0% | 46.6 | 101,417 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 43.95 per share. | 04 May 2026 | 2,076 | 105,211 (0%) | 0% | 43.9 | 91,240 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 13 Apr 2026 | 37,500 | 119,211 (0%) | 0% | 41.1 | 1,540,125 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 13 Apr 2026 | 37,500 | 119,211 (0%) | 0% | 41.1 | 1,540,125 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 13 Apr 2026 | 20,000 | 20,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.96 per share. | 13 Apr 2026 | 20,000 | 149,211 (0%) | 0% | 18.0 | 359,200 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.96 per share. | 13 Apr 2026 | 20,000 | 149,211 (0%) | 0% | 18.0 | 359,200 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2026 | 14,000 | 119,211 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2026 | 14,000 | 119,211 (0%) | 0% | 0 | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 13 Apr 2026 | 10,000 | 0 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 13 Apr 2026 | 10,000 | 129,211 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 13 Apr 2026 | 10,000 | 129,211 (0%) | 0% | 19.1 | 190,800 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 13 Apr 2026 | 7,500 | 156,711 (0%) | 0% | 15.5 | 115,950 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 13 Apr 2026 | 7,500 | 37,500 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 13 Apr 2026 | 7,500 | 156,711 (0%) | 0% | 15.5 | 115,950 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 13 Apr 2026 | 7,215 | 111,996 (0%) | 0% | 41.9 | 302,516 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 13 Apr 2026 | 7,215 | 111,996 (0%) | 0% | 41.9 | 302,516 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.62 per share. | 13 Apr 2026 | 5,226 | 106,770 (0%) | 0% | 41.6 | 217,506 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 41.62 per share. | 13 Apr 2026 | 5,226 | 106,770 (0%) | 0% | 41.6 | 217,506 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 42.53 per share. | 13 Apr 2026 | 1,559 | 105,211 (0%) | 0% | 42.5 | 66,304 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 42.53 per share. | 13 Apr 2026 | 1,559 | 105,211 (0%) | 0% | 42.5 | 66,304 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 01 Apr 2026 | 10,000 | 115,211 (0%) | 0% | 15.5 | 154,600 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 01 Apr 2026 | 10,000 | 105,211 (0%) | 0% | 30 | 300,000 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 01 Apr 2026 | 10,000 | 45,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 01 Apr 2026 | 10,000 | 115,211 (0%) | 0% | 15.5 | 154,600 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 01 Apr 2026 | 10,000 | 105,211 (0%) | 0% | 30 | 300,000 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 28.09 per share. | 16 Mar 2026 | 10,000 | 105,211 (0%) | 0% | 28.1 | 280,861 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 16 Mar 2026 | 10,000 | 10,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 16 Mar 2026 | 10,000 | 115,211 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 16 Mar 2026 | 10,000 | 115,211 (0%) | 0% | 19.1 | 190,800 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 28.09 per share. | 16 Mar 2026 | 10,000 | 105,211 (0%) | 0% | 28.1 | 280,861 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 17 Feb 2026 | 10,000 | 115,211 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 17 Feb 2026 | 10,000 | 20,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 17 Feb 2026 | 10,000 | 115,211 (0%) | 0% | 19.1 | 190,800 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 17 Feb 2026 | 5,679 | 109,532 (0%) | 0% | 27.5 | 156,195 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 17 Feb 2026 | 5,679 | 109,532 (0%) | 0% | 27.5 | 156,195 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 28.26 per share. | 17 Feb 2026 | 4,321 | 105,211 (0%) | 0% | 28.3 | 122,120 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 28.26 per share. | 17 Feb 2026 | 4,321 | 105,211 (0%) | 0% | 28.3 | 122,120 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 04 Feb 2026 | 2,485 | 105,720 (0%) | 0% | 32.1 | 79,694 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 04 Feb 2026 | 2,485 | 105,720 (0%) | 0% | 32.1 | 79,694 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 04 Feb 2026 | 509 | 105,211 (0%) | 0% | 32.7 | 16,665 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 04 Feb 2026 | 509 | 105,211 (0%) | 0% | 32.7 | 16,665 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 31 Jan 2026 | 66,960 | 66,960 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 25,110 | 115,380 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 25,110 | 115,380 (0%) | 0% | 0 | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.12 per share. | 31 Jan 2026 | 7,175 | 108,205 (0%) | 0% | 32.1 | 230,461 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 32.12 per share. | 31 Jan 2026 | 7,175 | 108,205 (0%) | 0% | 32.1 | 230,461 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 20 Jan 2026 | 10,000 | 100,270 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 27.34 per share. | 20 Jan 2026 | 10,000 | 90,270 (0%) | 0% | 27.3 | 273,420 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 20 Jan 2026 | 10,000 | 30,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 20 Jan 2026 | 10,000 | 100,270 (0%) | 0% | 19.1 | 190,800 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 27.34 per share. | 20 Jan 2026 | 10,000 | 90,270 (0%) | 0% | 27.3 | 273,420 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 22 Sep 2025 | 10,000 | 40,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Sep 2025 | 10,000 | 89,878 (0%) | 0% | 25 | 250,000 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 22 Sep 2025 | 10,000 | 99,878 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 22 Sep 2025 | 10,000 | 99,878 (0%) | 0% | 19.1 | 190,800 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Sep 2025 | 10,000 | 89,878 (0%) | 0% | 25 | 250,000 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 4,920 | 89,482 (0%) | 0% | 21.1 | 103,566 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 94,402 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 94,402 (0%) | 0% | - | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | Chief Legal Officer and GC | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 4,920 | 89,482 (0%) | 0% | 21.1 | 103,566 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | 10 Feb 2025 | 8,000 | 0 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 97,482 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 8,000 | 89,482 (0%) | 0% | 23.5 | 188,240 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 97,482 (0%) | 0% | - | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 8,000 | 89,482 (0%) | 0% | 23.5 | 188,240 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 98,433 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 98,433 (0%) | 0% | 0 | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 31 Jan 2025 | 8,951 | 89,482 (0%) | 0% | 19.8 | 177,051 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 31 Jan 2025 | 8,951 | 89,482 (0%) | 0% | 19.8 | 177,051 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 2,437 | 76,933 (0%) | 0% | 19.5 | 47,424 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 2,437 | 76,933 (0%) | 0% | 19.5 | 47,424 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 83,020 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 4,387 | 78,633 (0%) | 0% | 11.5 | 50,538 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 81,034 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 31 Jan 2024 | 2,590 | 76,270 (0%) | 0% | 8.9 | 22,947 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 2,174 | 78,860 (0%) | 0% | 8.5 | 18,548 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & CORPORATE SECRETARY | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 23 Jan 2024 | 2,062 | 56,034 (0%) | 0% | 9.0 | 18,476 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 3,300 | 59,911 (0%) | 0% | 0 | - | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 14.71 per share. | 31 Aug 2023 | 1,815 | 58,096 (0%) | 0% | 14.7 | 26,699 | - |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 825 | 56,611 (0%) | 0% | 16.6 | 13,687 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 60,026 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 31 Jan 2023 | 2,590 | 57,436 (0%) | 0% | 22.3 | 57,628 | Common Stock |
| Travere Therapeutics Inc | Ms. Elizabeth E. Reed | SVP, GC & Corporate Secretary | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 24 Jan 2023 | 2,062 | 39,776 (0%) | 0% | 21.5 | 44,333 | Common Stock |